

For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

 Filing Date
 Group Art Unit

 Sheet
 1
 OF
 17
 December 30, 2003
 1645 / 632

7		U.S.	Patent Documen	its		,
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Off	3,972,859	Aug 3, 1976	Fujino et al.			
T	3,992,365	Nov 16, 1976	Beddell et al.			
	4,003,884	Jan 18, 1977	Konig et al.			
	4,005,063	Jan 25, 1977	Gendrich et al.			
	4,008,209	Feb 15, 1977	Fujino et al.			
	4,010,125	Mar 1, 1977	Schally et al.			
	4,010,149	Mar 1, 1977	Baba et al.			
	4,018,726	Apr 19, 1977	Schally et al.			

ζ		Foreign	Patent Docum	nents			
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER				00000000	YES	NO
OM	76177/91	Nov 19, 1992	Australia				
	56394/94	Sep 1, 1994	Australia				
	181236	May 14, 1986	Europe				
	217659	Apr 8, 1987	Europe				
U	364819	Apr 25, 1990	Europe				

			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
0/1	,	A1	Aboudkhil et al., (1991) Scand. J. Immunol. 34, 647-653
1		A2	Akashi et al., (1997) Cell 89(7) 1033-1041
• [АЗ	Ali et al., (2000) Transplantation 69:221
		A4	Alpdogan et al., (2001) Blood 98:2256
1		A 5	Amado et al., (1999) Front. Biosci. 4:D468-475
		A7	Andersen, (1994) Infect. Immunity, 62:2536
	/	A8	Andrew et al., (2002) Exp. Gerontol. 37:455
1	7	A9	Andrew, D. and Aspinall, R., (2001) J. Immunol. 166(3): 1524-1530

EXAMINER //	DATE CONSIDERED	
Valto	8/10/07	
EVAMINED: Initial if aitation is appoint	d whether as not situation in in south-was with MDED	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

17

2

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645/632

			U.S. F	Patent Documer	nts		
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Į	Op	4,024,121	May 17, 1977	Schally et al.			
		4,089,946	May 16, 1978	Foell et al.	, "		
ĺ		4,100,274	Jul 11, 1978	Dutta et al.			
ľ		4,118,483	Oct 3, 1978	Konig et al.			
ľ		4,128,638	Dec 5, 1978	Moody			
I		4,218,439	Aug 19, 1980	Rivier et al.			
I		4,234,571	Nov 18, 1980	Nestor et al.			
I	7)	4,275,001	Jun 23, 1981	Konig et al.			

		Foreign	Patent Docume	ents			
EXAMINER	DOCUMENT DA	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL		JANE .			30000000	YES	NO
01	413209	Feb 20, 1991	Europe				
	7923545	Sep 21, 1979	France				
	2509783	Sep 11, 1975	Germany			·	
	9112825	Jul 31, 1991	Great Britain				
\overline{V}	9112859	Jul 31, 1991	Great Britain				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
OA	A10	Aspinall, et al., (2000) Vaccine 18:1629
	A11	Aspinall, R., (1997) <i>J. Immunol.</i> 158:3037
	A12	Atassi et al., (2001) Crit. Rev. Immunol. 21:1
	A13	Atlan-Gepner, C., Naspetti, M., et al., (1999) Autoimmunity 3:249-260
	A14	Bach (1983) Birth Defects Original Article Ser. 19(3): 245-253
	A15	Bahnson <i>et al.</i> , (1997) "Method for Retrovirus-Mediated Gene Transfer to CD34+- Enriched Cells," in <u>Gene Therapy Protocol</u> s (P.D. Robbins, ed.), Humana Press, pp.249-263
Ų	A16	Banerjee et al., (1994) Stem Cells 12:378

EXAMINER / 12	DATE CONSIDERED,
Voue A	8/10/07
EXAMINER: Initial if citation is considered	whether or not citation is in conformance with MPEP &

609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

3

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

		U.S. I	Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Dη	4,490,291	Dec 25, 1984	Fujino		1	
7	4,608,251	Aug 26, 1986	Mia			
	4,642,332	Feb 10, 1987	Folkers et al.			
	4,656,247	Apr 7, 1987	Folkers et al.			
	4,775,361	Oct 4, 1988	Jacques et al.			
	4,866,160	Sep 12, 1989	Coy et al.			
	4,992,421	Feb 12, 1991	De et al.			
. 1//	5,003,011	Mar 26, 1991	Coy et al.			

		Foreign F	Patent Docum	ents			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE 6 Feb 25, 1988	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
01	WO 88/01176						
7	WO 92/19746	Nov 12, 1992	wo				
(WO 93/15722	Aug 19, 1993	WO				
	WO 94/26285	Nov 24, 1994	wo				

•		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
On	A17	Basch, Ross S. (1990) Aging: Immunology and Infectious Disease, Vol. 2, No. 4, 229-235
1	A18	Batard et al., (2000) J. Cell. Sci. 113:383-90
	A19	Bauer, G., et al., (1997) Blood 89:2259-2267
	A20	Belmont and Jurecic (1997) "Methods for Efficient Retrovirus-Mediated Gene Transfer to Mouse Hematopoietic Stem Cells," in <u>Gene Therapy Protocols</u> (P.D. Robbins, ed.), Humana Press, pp. 223-240
V	A21	Berzins et al., (1999) Proc. Natl. Acad. Sci. USA (17): 9787-9791

	<u>/</u>	
EXAMINER	7	DATE CONSIDERED
V av 1		(// 0/0 (

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

4

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003

Group Art Unit 1645 7632

		U.S.	Patent Documen	ts			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
0.4	5,061,620	Oct 29, 1991	Tsukamoto et ál.	•			
	5,073,624	Dec 17, 1991	Coy et al.				
	5,144,019	Sep 1, 1992	Rossi et al.				
	5,199,942	Apr 6, 1993	Gillis				
	5,258,492	Nov 2, 1993	Schally et al.		·		
	5,736,524	Apr. 7, 1998	Content et al.				
	5,399,493	Mar 21, 1995	Emerson et al.				
	5,410,016	Apr 25, 1995	Hubbell et al.				
	5,506,207	Apr 9, 1996	Rivier et al.				

		Foreign	Patent Docum	nents			
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY		SUBCLASS	YES	NO
0.7	WO 94/26877	Nov 24, 1994	wo				
1	WO 95/08105	Mar 23, 1995	wo				
	WO 96/14853	Mar 23, 1996	· WO				
	WO 96/33281	Oct 24, 1996	WO				
V	WO 96/33282	Oct 24, 1996	WO				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
an	A22	Berzins, S.P., Boyd, R.L. and Miller, J.F.A.P., (1998) <i>J Exp. Med.</i> 187: 1839
7	A23	Bloom and Murray, (1993) Science 257, 1055
	A24	Bodey et al., (1997) In Vivo 11(4): 351-370
	A25	Bodey et al., (1997) In Vivo 11(5): 421-440
	A26	Bolotin et al., (1996) Blood 88:1887
	A27	Bolotin et al., (1999) Bone Marrow Transplant, 23(8): 783-788
U	A28	Bonato et al., (1998) Infection and Immunity, 66(1): 169-175

EXAMINER (a	et	DATE CONSIDERED
		U/ /

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

5

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

		U.S. F	Patent Documer	nts			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
01	5,559,703	Sep 24, 1996	lwata et al.				
	5,614,187	Mar 25, 1997	Sachs				
	5,614,502	Mar 25, 1997	Flotte et al.				
	5,624,823	Apr 29, 1997	Sachs et al.				
	5,643,252	Jul 1, 1997	Waner et al.				
,	5,658,564	Aug 19, 1997	Sykes et al.				
V	5,658,822	Aug 19, 1997	Wu et al.				

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	J2		02.00	00000.00	YES	NO
0.,7	WO 98/08533	Mar 5, 1998	WO		1		
	WO 98/23325	Jun 4, 1998	WO				
	WO 99/29728	Jun 17, 1999	WO				
	WO 99/32619	Jul 1, 1999	. WO				
V ·	WO 99/53050	Oct 21, 1999	WO				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
QM	A29	Bonyhadi, M.L., <i>et al.</i> , (1997) <i>J. Virology</i> 71:4707-4716
	A30	Borremans et al., (1989) Infect. Immunity 57:3123
	A31	Boyd, R.L., Tucek, C.L., Godfrey, D.I., Wilson, T.J, Davidson, N.J., Bean, A.G.D., Ladyman, H.M., Ritter, M.A. and Hugo, P., (1993) <i>Immunology Today</i> 14:445
	A32	Bruijntjes, J.P., Kuper, C.J., Robinson, J.E. and Schutirman, H.J., (1993) <i>Dev. Immunol.</i> 3:113
	A33	Capecchi, M.R., (1980) <i>Cell</i> 22:479-488
	A34	Carayon, P., and Bord, A., (1992) <i>J. Imm. Methods</i> 147:225

EXAMINER //	DATE CONSIDERED
Δ	
// 1	- 6/ /-7
1/4./5	S. Y. I OUT
EYAMINER: Initial if citation is considered	whather or not citation is in conformance with MPER &

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

6

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645 1632

		U.S.	Patent Document	s	-	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
0.7	5,658,892	Aug 19, 1997	Flotte et al.			
1	5,681,559	Oct 28, 1997	DiGiusto et al.			
	5,736,524	Apr 7, 1998	Content et al.			•
	5,741,706	Apr 21, 1998	Leavitt et al.			
	5,811,275	Sep 22, 1998	Wong-Staal et al.			
	5,814,617	Sep 29, 1998	Hoffman et al.			
V	5,839,446	Nov 24, 1998	Waner et al.			

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COONTIN	OLAGO	SOBOLAGO	YES	NO
01	WO 01/34815	May 17, 2001	wo				
DM	WO 03/51272	Jun 26, 2003	WO				

			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
a	M	A35	Castle, S.C., (2000) Clin Infect Dis 31(2): 578-585
		A36	Charoenvit et al., (1991) J. Immunol. 146: 1020
		A37	Coleman et al., (1989) Ultrasound Med. Biol. 15:213-227
		A38	Consolini et al., (2000) Clin. Exp. Immunol. 121(3): 444-447
		A39	Davis et al. (1998) Hum. Gene Ther., p. 1197-207
		A40	Dawe et al., (1993) Springer Semin. Immunopathol. 14:285
	<i>//</i>	A41	Denis et al., (1998) Infection and Immunity, (66)4:1527-1533

XAMINER	//	7	- f	DATE CONSIDERED

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

17

7

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

	U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
nΛ	5,876,708 Mar 2, 1999 Sachs						
07	6,030,833	Feb 29, 2000	Seebach et al.				
	6,056,738	May 2, 2000	Marchitto et al.				
	6,251,099	Jun 26, 2001	Kollias et al.				
	6,296,846	Oct 2, 2001	Sachs et al.				
	6,306,651	Mar 23, 2001	Sachs			χ	
,	6,315,772	Nov 13,2001	Marchitto et al.				
	6,492,145	Dec 10, 2002	Lowrie				

Foreign Patent Documents							
EXAMINER INITIAL	DATE COUNTRY CLASS SUBCLASS						
		_					

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
$\rho \wedge$	A42	DeWit et al., (1994) DNA Seq. 4:267
	A43	DiGusto et al., (1997) Blood 87:1261
	A44	Doria, G., Mancini, C., Utsuyama, M., Frasca, D. and Hirokawa, K, (1997) <i>Mech. Age. Dev.</i> 95: 131-142
	A45 Douek et al., (2000) Lancet 355:1875	
	A46	Douek et al., (2001) J. Immunol. 167:6663-8
	A47	Douek, D.C., McFarland, R.D., Keiser, P.H., Gage, E.A., Massey, J.M., Haynes, B.F., Polis, M.A., Haase, A.T., Feinberg, M.B., Sullivan, J.L., Jamieson, B.D., Zack, J.A., Picker, L.J. and Koup, R.A., (1998) <i>Nature</i> 396:690
	A48	Dougherty and Parks, (1995) Curr. Opin. Cell Biol. 7:399
	A49	Doukas et al., (1995) Ultrasound Med. Biol. 21:961
1	A50	Dreger et al., (1993) Blood 81:1404
	A51	Ellis et al., (2001) Int. Immunol. 13:553-558

EXAMINER /		DATE CONSIDERED	
. / /	11	6/1/1/	
1/ ve	ν ()	8/10/07	
			

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

8

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645 /632

U.S. Patent Documents						
EXAMINER INITIAL	DATE NAME CLASS SUBCLASS TENTO					
DM	6,558,663	May 6, 2003	Seebach et al.			13.1

Foreign Patent Documents							
EXAMINER DOCUMENT DATE COUNTRY CLASS SUBCLASS TRANSLA					LATION		
INITIAL NUMBER		DATE COUNTY		CEASS	SUBCLASS	YES	NO
1			,				
L I					1 1		

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
07	A52	Engel et al., (1999) Frontiers in Bioscience 4, e26-33
	A53	Erben et al., (2001) Horm. Metab. Res. (2001) 33:491
	A55	Ernst et al., (1990) J. Immunol. 145:1295
	A55	Fabris et al., (1997) Cell Mol. Biol., 43(4): 529-541
		Fabris and Mocchegiani, (1995) Aging Apr; 7(2): 77-93
	A56	Fabro et al., (1990) J. Appl. Phys. 68:775,
	A57	Faith et al., (1991) Immunol. 74:1
	A58	Faltynek et al., (1992) J. Immunol. 149:1276
	A59	Fan et al., (2002) J. Immunol. 168:755-62
	A60	Fearon and Locksley (1996) Science 272:50
	A61 -	Fernando et al., (1999) Clin. Exp. Immunol. 115:397
	A62	Fitzpatrick et al., (1987) J. Endocr. 113, 51-55
	A63	Flurkey et al., (1992) J. Gerontol, 47:B115
	A64	Flynn et al., (1992) Proc. Natl. Acad. Sci. USA 89:12013
	A65	Franke et al., (2000) Infect. Immun. 68:3403
	A66	Fredrickson, G.G. and Basch, R.S., (1994) <i>Development and Comparative Immunology</i> 18:251
	A67	Fry et al., (2001) Blood 97(6): 1525-1533
	A68	Fry, et al., (2001) Trends Immunol. 22(10): 564-571
	A69	Garrovillo et al., (1999) Transplantation 68:1827
	A70	Garrovillo et al., (2001) Am. J. Transplant. 1:129

EXAMINER Dank	DATE CONSIDERED
EXAMINEA: Initial if citation is considered, wheth 609: Draw Line through citation if not conformance	ner or not citation is in conformance with MPEP § and not considered. Include copy with next

BOSTON 1967614v1

communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

17

9

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

BA	A71	Garzetti et al., (1996) Obstet. Gynecol. 88: 234-40				
	A72	George, A. J. and Ritter, M.A., (1996) Immunol. Today 17:267				
	A73	Gill et al., (2002) Nat. Immunol. 3:635				
	A74	Girasole et al., (1992) J. Clin. Invest. 89:883				
	A75	Godfrey, D. I, and Zlotnik, A., (1993) Immunol. Today 14:547				
	A76	Godfrey, D.I, Izon, D.J., Tucek, C.L., Wilson, T.J. and Boyd, R.L., (1990) Immunol. 70:66				
		Goldberg et al., (2003) Poster Presentation, ASBMT, Keystone USA				
	A77	Goldberg et al., (2003) Abstract, ASBMT, Keystone USA				
	A78	Goldberg et al., (2002) Abstract/Poster Presentation ASH, Philadelphia USA				
	A79	Goldberg et al., (2002) Abstract of Oral Presentation, Immunology Group of Victoria, Beachworth AU				
•	A80	Graham, F.L. and Van Der Eb, A.J., (1973) <i>Virology</i> 52:456-457				
	A81	Greenstein et al., (1987) J. Endocr., 112, 345-350				
	A82	Greenstein et al., (1986) J. Endocr. 110, 417-422				
	A83.	Grossman, Charles J. (1984) Endocrine Reviews, 5(3): 435-455				
	A84	Grossman, Charles J. (1985) Science 227: 256-261				
	A85	Hadden, John W. (1998) New York Academy of Sciences, 840: 352-358				
	A86	Hannet et al., (1992) Immunol. Today, June; 13(6): 215-218				
	A87	Haseloff and Gerlach (1988) Nature 334:585				
	A88	Haynes, B.F., Hale, L.P., Weinhold, K.J., Patel, D.D., Liao, HX., Bressler, P.B., Jones, D.M., Demarest, J.F., Gebhard-Mitchell, K., Haase, A.T. and Bartlett, J.A., (1999) <i>J. Clin. Invest.</i> 103: 453-460				
	A89	Hazenberg et al., (2001) J. Mol. Med. 79:631-40				
1	A90	Heitger, A., Neu, N., Kern, H. and Fink, F.M., (1997) <i>Blood</i> 90: 850-857				

<u> </u>	
EXAMINER //	DATE CONSIDERED/
Var to	8/1907
EXAMINER: Initial if citation is considered, wheth	er or not citation is in conformance with MPEP §
609: Draw Line through citation if not conformance a	and not considered. Include copy with next
communication to applicant.	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

10

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645/632

01	ን	A91	Heitger, A., Winklehner, P., et al., (2002) <i>Blood</i> 99:4053-4062
		A92	Hertogh-Huijbregts et al., (1990) Mech. Ageing Dev. 53:141-155
		A93	Hirokawa, K. and Makinodan, T., (1975) J. Immunol. 114:1659
		A94	Hirokawa, (1998) "Immunity and Ageing," in PRINCIPLES AND PRACTICE OF GERIATRIC MEDICINE, (M. Pathy, ed.) John Wiley and Sons Ltd.
		A95	Hirokawa, K., Utsuyama M., Kasai, M., Kurashima, C., Ishijima, S. and Zeng, YX., (1994) Immunology Letters 40:269
		A96	Hobbs, M.V., Weigle, W.O., Noonan, D.J., Torbett, B.E., McEvilly, R.J., Koch, R.J., Cardenas, G.J. and Ernst, D.N., (1993) <i>J. Immunol.</i> 150:3602
		À97	Hochberg et al., (2001) Blood 98:1116-21
		A98	Hoffman et al., (1991) Science 252: 520
		A99	Homo-Delarche et al., (1993) Springer Sem. Immunopathol. 14:221
		A101	Hsu et al., (2000) Cancer Res. 60:3701
		A102	Hu et al., (1993) Int. Immunol. 5:1035-1039
		A103	Huiskamp, R., Davids, J.A.G. and Vos, O., (1983) Radiation Research 95:370
		A104	Huiskamp <i>et al.</i> , (1985) <i>J. Immunol.</i> , 134(4): 2161-2171
		A105	Huygen et al., (1992) Infect. Immunity 60:2880
		A106	Igarashi et al., (2001) Proc. Natl. Acad. Sci. USA, 98(26): 15131-15136
		A107	Jacobson et al. (1999) Endocrinology, 140(8): 3429-3437
	T	A108	Jacobson et al., (1999) J. Allergy Clin. Immunol., 104(3): Pt. 1, 653-658
	1	A109	Jacobson et al., (1994) Endocrinology, Vol. 184(6): 2516-2523
	IJ	A110	Janeway et al., (2001) Immunobiology 5th Ed., p. 325

	\ <u> </u>	
EXAMINER	1h	DATE CONSIDERED
		······································

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

17

11

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645 /632

A111	Jansson et al., (1994) J. Neuroimmunology 53:203-207
A112	Jenkinson et al., (1985) Transplantat. 39:331
A113	Junker et al., (1998) <i>Hum Gene Ther.</i> , p. 333-40
A114	Kamradt, T. and Mitchison, N.A., (2001) N. Engl. J. Med. 344:655-664.
A115	Kendall et al., (1990) Cell Tissue Research, 261(3)555-64
A116	Kendall, (1988) "Anatomical and physiological factors influencing the thymic microenvironment," in THYMUS UPDATE I, Vol. 1. (M. D. Kendall, and M. A. Ritter, eds.) Harwood Academic Publishers, p. 27
A117	Kincade et al., (2002) Immunology, 14: 385-394
A118	Kincade et al. (2000) Immunological Reviews, 175: 128-137
A119	Kirschmann et al., (1992) Cell. Immunol. 139:426
A120	Kissin <i>et al.</i> , (1987) <i>Radiology</i> , 163(1): 67-70
A121	Kohen et al., (1998) Developmental Immunology, 5: 277-285
A122	Kohn, D.B., et al., (1999) Blood 94:368-371
A124	Komschlies et.al., (1995) J. Leukoc. Biol. Dec.; 58(6): 623-633
A125	Kouro et al., (2001) Blood 97:2708
A126	Krijanovski, et al., (1999) Blood 94:825
A127	Krug (2004) Sem. Oncol. 31:112
A128	Kurashima, C, Utsuyama, M., Kasai, M., Ishijima, S.A., Konno, A. and Hirokawa, A., (1995) Int. Immunol. 7:97
A129	Landstrom et al., (1997) Int. J. Cancer 71, 451-455
A131	LeMaoult <i>et al.</i> , (1999) <i>J. Immunol</i> . 162:6384-6391
A132	LeMaoult et al., (2000) J. Immunol. 165:2367
A133	Leposavic et al., (1995) Neuroimmunodulation 2:100-107
	A112 A113 A114 A115 A116 A117 A118 A119 A120 A121 A122 A124 A125 A126 A127 A128 A129 A131 A132

EXAMINER // /	DATE CONSIDERED
Vail to	8/10/07
EXAMINER: Initial if citation is considered, wheth	er or not citation is in conformance with MPEP §
609: Draw Line through citation if not conformance	

BOSTON 1967614v1

communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

12

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

0M	A134	Lewin et al., (2002) Blood 100:2235
	A135	Lin et al., (1996) Cancer Res. 56:21
	A136	Lincz et al., (2001) Leuk. and Lymph. 40: 373
	A138 Mackall et al., (1997) Immunology Today, 18(5): 245-251	
	A139	Mackall, C.L. and Gress, R.E., (1997) Immunol. Rev. 160:91
	A140	Mackall, C.L. et al., (1995) New England J. Med. 332:143
	A1 41	Mackall, C.L., Punt, J.A., Morgan, P., Farr, A.G. and Gress, R.E., (1998) Eur. J. Immunol. 28: 1886-1893
	A142	Maraskovsky et al., (1997) Cell 89(7): 1011-9
	A143	Martinez et al., (2003) <i>J. Clin Invest</i> . 111:1365
	A144	Masuzawa et al., (1994) J. Clin. Invest. 94:1090
	A145	Matera L, Neuroimmunomodulation (1997) 4(4): 171-80
	A146	Matzinger et al., (1989) Nature 338:74-60
	A147	Medina et al., (2001) Nat. Immunol. 2:718
·	A148	Mercader et al., (2001) PNAS 98(25): 14565-14570
	A149	Miller et al., (1976) J. Immunol. 117:1519
	A150	Mocchegiani et al., (1990) Horm. Res. 33(6): 248-55
	A152	Morale et al., (1991) Endocrinology, 128(2): 1073-1085
	A153	Morelli et al., (2001) Semin. Immunol. 13:323-335
	A154	Morrissey et al., (1991) J. Immunol. 146:1547
	A155	Mosley et al., (1998) Cell. Immunol. 189:10
	A156	Murasko, D.M., Bernstein, E.D., et al., (2002) Exp. Gerontol. 37:427-439
1	A157	Nabel, E.G. et al., (1992) Hum. Gene Ther. 3:649-656
J	A158	Nicoletti et al., (1993) J. Immunol. 150:543-549

EXAMINER /	DATE CONSIDERED
	-/1-/-2
\/a/./\\\\\\	1 8//0/07
	7. /

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

13

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date
December 30, 2003

Group Art Unit 1645 //3

A159 Nikolic et al., (2000) Blood, 96(3): 1166-1172 A160 Noach et al., (2002) Blood 100:312 A161 Nowak, Rachel (1999) New Scientist, pg. 11 A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Ostenwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panerai et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci., U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930 V A183 Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676			
A161 Nowak, Rachel (1999) New Scientist, pg. 11 A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930	DM	A159	Nikolic <i>et al.</i> , (2000) <i>Blood</i> , 96(3): 1166-1172
A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930	i	A160	Noach et al., (2002) Blood 100:312
A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A161	Nowak, Rachel (1999) New Scientist, pg. 11
A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24		A162	Oberbeck R., (2003) J. Surg Res. 113(2): 248-56
A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24		A163	Ohnishi et al (2003) Int. J. Mol. Med. 1:331
A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Orlman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A164	
A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Orlman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			
A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Orlman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			
A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Orlman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24		A166	
A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci., U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A167	Oluwole et al., (1993) Transplantation 56:1523-1527
A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A168	Oosterwegel et al., (1997) Immunity 6(3): 351-360
A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A169	Orme et al., (1993) J. Infect. Dis. 167:1481
A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A170	Ortman et al., (2002) Int. Immunol. 14:813
A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A171	Pacheco et al., (1979) J. Parisitol. 65:414
A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A172	Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192
A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A173	Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457
A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A174	Panoskaltsis-Mortari et al., (2000) Blood 96:4350
A177 Penit, C. and Ezine, S., (1989) <i>Proc. Natl. Acad. Sci, U.S.A.</i> 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) <i>Dev. Immunol.</i> 5:25 A179 Perriman <i>et al.</i> , (1992) <i>Gene</i> 113:157 A180 Peschon <i>et al.</i> , (1994) <i>J. Exp. Med.</i> 180(5): 1955-1960 A181 Plosker, G.L. and Brogden, R.N., (1994) <i>Drugs</i> 48:930		A175	Parkman et al., (1997) Immunol. Rev. 157:73
A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A176	Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269
A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A177	Penit, C. and Ezine, S., (1989) <i>Proc. Natl. Acad. Sci, U.S.A.</i> 86:5547
A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A178	Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25
A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A179	Perriman et al., (1992) Gene 113:157
// A182 Plosker, G.L. and Brogden, R.N., (1994) <i>Drugs</i> 48:930		A180	Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960
		A181	Plavec et al., (1996) Gene Ther, p. 717-24
V A183 Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676		/ A182	Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930
	V	A183	Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676

EXAMINER /	DATE CONSIDERED
\(/ /	
	T/10/13
Vave I	1/1907
EVALUATED A MARKET TO THE STATE OF THE STATE	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

14

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

619	A184	Potter, H., Weir, L., and Leder, P., (1984) Proc. Natl. Acad. Sci. USA 81:7161-7165	
	A185	Prasad et al., (1988) J. Clin. Invest. Oct; 82(4): 1202-1210	
	A186	Randle-Barrett and Boyd (1995) Dev. Immunol. 4:101	
A188		Ranga et al., (1998) Proc. Natl. Acad. Sci. USA 95:1201	
	A189	Rao et al., (1994) Am. J. Reproductive Immunology, 32:238-247	
	A190	Renia et al., (1993) J Immunol. 150:1471	
	A191	Repique et al., (2002) Infection and Immunity, p. 3318-3323	
	A192	Robinson, et al. (2000) Adv. Virus Res. 55:1-74	
	A193	Rodrigues et al., (1991) Int. Immunol. 3: 579	
	A194	Romain et al., (1993) Proc. Natl. Acad. Sci. USA 90:5322	
	A195	Rosenzweig et al., (1997) Blood, 90(12): 4822-4831	
	A196	Rossi, S., Blazar, B.R., et al., (2002) Blood 100:682-691	
	A197	Sato et al., (2004) Br. J. Cancer 90:1334	
	A198	Scollay, R.G., Butcher, E.C. and Weissman, I.L., (1980) Eur. J. Immunol. 10:210	
	A199	Seder and Paul (1994) Annu. Rev. Immunol. 12:635	
	A200	Segeren et al., (1999) Br. J. Haem. 105: 127-130	
	A201	Sempowski et al., (2002) Mol. Immunol. 38:841-84	
	A202	Sempowski, G.D., Hale, L.P., Sundy, J.S., Massey, J.M., Koup, R.A., Douek, D.C., Patel, D.D. and Haynes, B.F., (2000) <i>J. Immunology</i> 164: 2180-2187	
	A203	Shaffer and Scher (2003) Lancet Oncol. 4:407	
	A204	Shippy et al., (1999) Mol. Biotechnol.12: 117	
	A205	Shortman, K., Egerton, M., Spangrude, G.J. and Scollay, R., (1990) Seminars in Immuno. 2:3	
A206 Shu et al., (1993) J. Virol. 67:2723		Shu <i>et al.</i> , (1993) <i>J. Virol.</i> 67:2723	
1/	A208	Shull et al., (1992) Nature 359:693	

	·
EXAMINER //	DATE CONSIDERED
	1 40/1-7
(Out / V	. 90901

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

15

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645 /632

		
D/5	A209	Silva and Lowrie, (1994) Immunol. 82:244
	A210	Smithson et al., (1995) J. Immunol. 155:3409
	A212	Smithson et al., (1998) J. Immunol. 161.27-35
	A213	Soares et al., J. Immunol. (1998) 161:5909-5917
	A214	Starzl, T.E., Demetris, A.J., Murase, N., Ricardi, C. and Truce, M., (1992) Lancet 339:1579
	A215	Steffens et al., (2000) Clin. Immunol. 97:95
	A216	Stern et al., (1989) Corneal Laser Ablation, 107: 587-592
	A217	Storek et al., (1997) Am. J. Hematol. 54:131
	A218	Storek et al., (2001) Blood 98:3505
	A219	Strayer, D.S., Branco, F. et al., (2002) Therapy 5:33-41
	A220	Suda and Zlotnik, (1992) J. Immunol. 149(1): 71-76
	A221	Suda, T., and Zlotnik, A., (1991) J. Immunol. 146:3068
	A222	Takeoka, Y., Taguchi, N. et al., (1999) Clin. Immunol. 90:388-398
	A223	Talwar, (1999) <i>Immunol. Rev.</i> 171:173-92
	A224	Tang et al., (1997) J. Immunol. 159:117
	A225	Tanghe, et al., (2001) Infection and Immunity, p. 3041-3047
	A226	Tanghe et al., (2000) Infection and Immunity 68(7): 3854-3860
	A227	THE JORDAN REPORT 2000: ACCELERATED DEVELOPMENT OF VACCINES, published by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (available at http://www.niaid.nih.gov/publications/pdf/jordan.pdf —last visited Apr. 2004)
	A228	Thomas-Vaslin, V., Damotte, D. et al., (1997) P.N.A.S. (U.S.A.) 94:4598-4603
/	A229	Thomson, A.W. and Lu, L., (1999) Immunology Today 20(1):27
	A230	Thurmond et al., (2000) Endocrinol. 141:2309

EXAMINER ()	DATE CONSIDERED	
1/ . 4	\Box	
Varil 1	01.0/07	•
	9.70	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

16

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

by	A231	Timm, J.A. and Thoman, M.L., (1999) J. Immunol. 162:711
	A232	Tomita et al., (1994) J. Immunol. 153:1087-1098
A233 To		Tosi et al., (1982) Clin. Exp. Immunol. Feb; 47(2): 497-504
	A235	Ulmer et al., (1993) Science 259:1745
	A236	Umesaki et al., (1999) Gynecol. Obstet. Invest. 48:66-8
	A237	Utsuyama et al, (1989) Mech. of Ageing Dev. 175-185
	A238	Utsuyama <i>et al.</i> , (1995) <i>Mech. Ageing Dev.</i> 107-117
	A239	van Ewijk <i>et al.</i> , (1991) <i>Annu. Rev. Immunol.</i> 9:591-615
	A240	van Ewijk, W., Rouse, R.V. and Weissman, I.L., 1980 J. Histochem. Oct 28(10): 1089
	A241	Viselli et al., (1997) Cellular Immunology 182, 99-104
	A242	Viselli et al. (1995) Immunology 84: 337-342
	A243	Vickery et al., (1984) LHRH AND ITS ANALOGS: CONTRACEPTIVE & THERAPEUTIC APPLICATIONS (Vickery et al., eds.) MTP Press Ltd., Lancaster, PA
4.	A244	Von Freeden-Jeffry, U., Vieira, P., Lucian, L.A., McNeil, T., Burdach, <i>E.G.</i> and Murray, R., (1995) <i>J. Exp. Med.</i> 181:151
	A245	Waldrop et.al., (1998) J. Immunol. 161(10): 5284-95
	A246	Wang et al., (2003) Br. J. Cancer 88:887
	A247	Waterhouse et al., (1998) Proc. Natl. Acad. Sci. USA 95:13959
	A248	Weinberg et al., (1995) Biol. Blood Marrow Transplant1 (1): 18-23
	A249	Weiss et al., (1988) Proc. Natl. Acad. Sci USA 85:573
	A250	Weiss et al., (1992) J. Immunol. 149:2103
	A251	Weksler et al., (2000) Vaccine 18:1624-1628
	A252	Weyand, C.M., Brandes, J.C., Schmidt, D., Fulbright, J.W. and Goronzy, J.J., (1998) Mech. Age. Dev. 102: 131-147

EXAMINER	11	DATE CONSIDERED
/ i/		Elids 7
	\mathcal{L}	. 0/1907

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

17

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

0/1		A253	Wiker and Harboe, (1992) Microbiol. Rev. 56: 648
1	4	A254	Wiles, M.V., Ruiz, P. and Imhof, B.A., (1992) Eur. J. Immunol. 22:1037
	4	A255	Wilson et al., (1995) Blood 85:1535
		A256	Windmill and Lee, (1998) Tissue Cell 30(1): 104-111
	-	A257	Windmill et al. (1993) Reprod. Fertil. Devl. 5, 73-81
	-	A258	Woffendin et al., (1994) Proc. Natl. Acad. Sci. USA, 91:11581
		A259	Woffendin et al., (1996) Proc. Natl. Acad. Sci. USA, 93:2889
	1	À260	Wu et al., (1996) Am. J. Repro. Immunol. 35(6): 510-516
		A261	Yang, NS. and P. Ziegelhoffer, (1994) "The Particle Bombardment System for Mammalian Gene Transfer," In PARTICLE BOMBARDMENT TECHNOLOGY FOR GENE TRANSFER (Yang, NS. and Christou, P., eds.), Oxford University Press, New York, pp. 117-141
	1/	A262	Young and Garbe, (1991) Res. Microbiol. 142:55
	/ /	A263	Zhang et al., (1999) J. Exp. Med. 190:725
V	//	A264	Zlotnik, A. and Moore, T.A., (1995) Curr. Opin. Immunol. 7:206.

EXAMINER)		DATE CONSIDERED	
LANGUALIA /	/	DATE CONSIDERED	
i // /		//./-	
l / / //	Δ	(////	
1/0/0		1 <i>X 11010</i> 7	
1/216-1		0/6/- (.	

ot. For, PTO-1449

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

1

Docket Numbers NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645 /632

	i.						
	EXAMINER INITIAL	DOCUMENT NUMBER	FILING DATE IF APPROPRIATE				
ſ	D.F	10/399,213	N/A	Boyd	N/A	N/A	Apr 14, 2003
Γ		10/748,450	· N/A	Boyd	N/A	N/A	Dec 30, 2003
Γ		10/749,118	N/A	Boyd	N/A	N/A	Dec 30, 2003
		10/749,119	N/A	Boyd	N/A	N/A	Dec 30, 2003
T		10/749,120	N/A	Boyd et al.	N/A	N/A	Dec 30, 2003
		10/748,831	N/A	Boyd	N/A	N/A	Dec 30, 2003

		Foreign	Patent Docum	nents			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS		LATION
1//	WO 00/62657	Oct 26, 2000	PCT			YES	NO
	2			-			

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
1.0	

			·	
EXAMINER	Ver to	DATE CONSIDERED		
EVAMINED				

	RMATION		NOR-014CP4 and 10/749,122 286336.153US1			
3 0 1005 B	IN AN APPI e several shee		•	Applicant Boyd		
The last				Filing Date	Group Art Unit	
TRAD WSheet	1	OF	1	December 30, 2003	1632	

•		U.S	S. Patent Docume	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	6,103,694	Aug 15, 2000	Mardiney, III et al.	514	12	Apr 10, 1998

Foreign Patent Documents								
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION	
INITIAL	NUMBER					YES	NO	

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
1	(A2	Ghalie et al., "Prevention of Hypermenorrhea With Leuprolide in Premenopausal Women Undergoing Bone Marrow Transplantation," American Journal of Hematology, 1993, Vol. 42, pp 350-353
	A2	Kojima et al., "Immunosuppressive Therapy Using Antithymocyte Globulin, Cyclosporine, and Danazol With or Without Human Granulocyte Colony-Stimulating Factor in Children With Acquired Aplastic Anemia," Blood, September 15, 2000, Vol. 96, No. 6, pp 2049-2054
	A2	Masera et al., "Is Orchiectomy Indicated Before BMT in Childhood ALL?" Bone Marrow Transplant, 1991, Vol. 8, No. S1, pp 33-35
	/ A2	Vogelsang et al., "Thalldomide Induction of Bone Marrow Transplantation Tolerance," Transplantation Proceedings, 1987, Vol. XIX, No. 1, pp 2658-2661

EXAMINER OUT	DATE CONSIDERED.					
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.						

Subt. For, PTO-144	19			Docket Number	Application Number
/ U &/ IN	MATION AN APPI		NOR-014CP4 10/749,122 286336.153		
AUG 1 5 Mus St Use so	everal shee	ets if nece	Applicant Boyd		
The market of				Filing Date	Group Art Unit
Sheet	1	OF	i	December 30, 2003	1645/632

		U.S. Pate	ent Documents	
Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
0/1	US-5,760,000	06/02/1998	Habibi	*
D1.	US-2005/0043245	02/24/2005	Siler-Khodr	
				-
				1
				. /

		Foi	reign Patent D	ocuments	
Examiner Initial	Cite No.	Foreign Patent Document Country Code-Number- Kind	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
PM		WO 01/74377	10/11/2001	PCT	
bA		WO 02/31110	04/18/2002	PCT	

Examiner's Initial		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
	·	

	/
EXAMINER ///	DATE CONSIDERED //
Kur	1 SKO/O+
EXAMINER: Initial if citation is considered, whether or not citat	ion is in conformance with MPEP § 609: Draw Line through
citation if not conformance and not considered. Include convivith	

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RKUSU	bstitute for form 1449A/B/PT	· O		Complete if Known		
		-		Application Number	10/749122-Conf. #3280	
11	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	December 30, 2003		
l s			First Named Inventor	Richard L. BOYD		
				Art Unit	1644 1672	
<u> </u>	(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned Montagani 6A		
Sheet	1	of	1	Attorney Docket Number	286336.153US1/NOR-014CP4	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DA	AA*	US-5,434,136	07-18-1995	Mathias	
	AB*	US-5,985,892	11-16-1999	Walsh et al.	·
T.	AC.	US-5,760,000	06-02-1998	Habibi	
V	AD*	US-2005/0043245	02-24-2005	Siler-Khodr	

	,	FOREK	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
UM	ВА	WO-01/74377	10-11-2001	Siler-Khodr and Khodr		П
DA	ВВ	WO-02/31110	04-18-2002	Boyd		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30. 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Sent Codes of USPT

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city	NON PATENT LITERATURE DOCUMENTS					
and/or country where published.	Examiner Initials	Cite No.1		Τ²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Sionature	. 25	One	16	Date Considered	8/10/07
E407121					

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

OIPE 420 2006 W

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

•	Complete if Known						
Application Number	10/749122-Conf. #3280						
Filing Date	December 30, 2003						
First Named Inventor	Richard L. BOYD						
Art Unit	1845 1632						
Examiner Name .	Not Yet Assigned Mostanni BA						
Attorney Docket Number	0286336.00153US1/NOR-014CP4						

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	™		
			•	*				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. In Italian is indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

•	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²		
DM		FITZPATRICK et al., "Reappearance of Thymus of Ageing Rats after Orchidectomy," Journal of Endocrinology, 1985, pp. R17-R19, Vol. 106.			
0/1		OLSEN et al., "Androgen Deprivation Induces Phenotypic and Functional Changes in the Thymus of Adult Male Mice," Endocrinology, 1991, pp. 2471-2476, Vol. 129, No. 5.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	1 hour	the	Date Considered	8/10/07
		Ţ— O		

^{*}Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

APR 2 7 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/749122-Conf. #3280			
Filing Date	December 30, 2003			
First Named Inventor	Richard L. BOYD			
Art Unit	1645 /632			
Examiner Name	Not Yet Assigned Moutawai, LA			
Attorney Docket Number	286336.153 US1/NOR-014CP4			

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.1		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
DM	AA*	US-6,248,329	06-19-2001	Chandrashekar et al.			

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Where H	Where Relevant Passages or Relevant Figures Appear	T°	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). *See India Codes of USPTO Patent Documents at www.uspto.gog or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
DA	CA	Ellis, "New Technologies for Making Vaccines," Chapter 29 of "Vaccines", Plotkin et al., 1998 pp. 568-574.			
	СВ	Ezzell NIH Research, "Cancer 'Vaccines': An Idea Whose Time Has Come?" 1995, Vol. 7, pp. 46-49.			
	CC	Feldman et al., "Anti-TNF∞ Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceeding, 1998, Vol. 30, pp. 4126-4127.			
V	CD	Spitler, "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 1995, Vol. 10, pp. 1-3.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Due No	Date Considered	8/10/7
	•		7 / 0

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	substitute for form 1449A/B/i	РТО		Complete if Known		
1				Application Number	10/749122-Conf. #3280	
1	INFORMATIO	N DIS	CLOSURE	Filing Date	December 30, 2003	
ļ	STATEMENT	BY A	PPLICANT	First Named Inventor	Richard L. BOYD	
1				Art Unit	1645 /612	
L	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned Monthsum 124	
Shee	et 1	of	1	Attomey Docket Number	0286336.00153US1/NOR-014CP4	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
m	ВА	WO-96/22786		TAKEDA CHEMICAL INDUSTRIES, LTD.		

*EXAMINER: Initial if reference considered, whether or not chation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicants unique citation designation number (optional): ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
			1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner		0 1/1	Date	GL. I
Signature	1/a		Considered	8/10/13
				7 / / /

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

JUN 2 6 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espend to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/E	3/PTO		Complete if Known		
		,		Application Number	10/749122-Conf. #3280	
11	IFORMATIO	ON DIS	SCLOSURE 1	Filing Date	December 30, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD	
				Art Unit	1645 /632	
	(Use as many	sheets as	necessary)	Examiner Name .	Not Yet Assigned Mentani A	
Sheet	1	of	1	Attorney Docket Number	0286336.00153US1/NOR-014CP4	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*	No.1	Number-Kind Code ² (# known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
m	AA.	US-4,049,805	09-20-1977	Strade				
01	AB*	US-5,759,551	06-02-1998	Ladd et al.				

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,				
Initials	No.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵			
6.1	ВА	EP-0882736A1	12-09-1998	LABORATORIE THERAMEX,		П			
				S.A.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optionat). ² See Kinds Codes of USPTO Patent Documents at www.usplo.govg.or/ or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
$D\Lambda$	CA	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.	
	СВ	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.	
V	CC	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	10	(4)		
Examiner Signature	Van		Date Considered	8/10/07
			Toonsidered	0//-/- 1

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Transtation is attached.

OIPE 420

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and U.S. DEPARTMENT OF COMMERCE
U.S. DEPARTMENT OF C

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

. (Use as many sheets as necessary)

Sheet 1 of

Complete if Known					
Application Number	10/749,122-Conf. #3280				
Filing Date	December 30, 2003				
First Named Inventor	Richard L. BOYD				
Art Unit	1632				
Examiner Name	Not Yet Assigned Month uni. I				
Attorney Docket Number	0286336.00153US1 / NOR-0140P4				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

		FOREIG	SN PATENT I	DOCUMENTS			
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pagas, Columns, Lines,		
Initials*	No.			Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
						_	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁰ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	. I manazina journal serial symposium catalog etc.) date page/s/ volume issue numbods) publ		T²			
01	CA	HARRISON, "The Prospect of Vaccination to Prevent Type 1 Diabetes", Human Vaccines, 1(4):143-150 (2005)				
	СВ	TIAN, et al., "Recombinant Human Growth Hormone Promotes Hematopoietic Reconstitution after Syngeneic Bone Marrow Transplantation in Mice", Stem Cells, 16:193-199 (1998)	Г			
	CC	VINCENT, et al., "Autoimmune Channelopathies and Related Neurological Disorders", Neuron, 52:123-138 (2006)				
U	CD	XIAO, et al., "Tolerogenic Dendritic Cells: The Ins and Outs of Outcome", J. Immunother, 29(5):465-471 (2006)	Γ			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		1		/ /
Examiner Signature	Verse		Date Considered	8/10/07
		7		

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.